ELN Pemfailan SEC - Elan Corp. Plc- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	529900ME30V6Y8RPTP62
CIK	737572

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Elan Corp. Plc

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

February 7, 2014	SC 13G/A	ELN / Elan Corp. Plc / WESTFIELD CAPITAL MANAGEMENT CO LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Elan Corporation, PLC (Name of Issuer) American Depositary Receipt (Title of Class of Securities) 284131208 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
December 30, 2013	15-12B	- 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-13896 ELAN CORPORATION, PLC (Exact Name of Registrant as Specifi
December 19, 2013	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 30, 2013, pursuant to the provisions of Rule 12d2-2 (a).
December 18, 2013	EX-99.1	PERRIGO COMPANY PLC COMPLETES ACQUISITION OF ELAN CORPORATION, PLC EX-99.1 2 d646802dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE PERRIGO COMPANY PLC COMPLETES ACQUISITION OF ELAN CORPORATION, PLC DUBLIN, IRELAND – December 18, 2013 - Perrigo Company plc (NYSE, TASE: PRGO) (“Perrigo”) and Elan Corporation, plc (“Elan”) today announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement
December 18, 2013	POS AM	- POST-EFFECTIVE AMENDMENT NO.1 TO FORM F-3 Post-Effective Amendment No.1 to Form F-3 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100252 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Post-Effective Amendment No. 1 to Form F-3 Registration Statement No. 333-100252 Elan Corporation, plc (Exact name of Registrant
December 18, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 Post-Effective Amendment No.1 to Form S-8 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100556 Registration No. 333-07361 Registration No. 333-121021 Registration No. 333-135184 Registration No. 333-135185 Registration No. 333-154573 Registration No. 333-181971 Registration No. 333-181973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
December 18, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (A
December 18, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 Post-Effective Amendment No.1 to Form S-8 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100556 Registration No. 333-07361 Registration No. 333-121021 Registration No. 333-135184 Registration No. 333-135185 Registration No. 333-154573 Registration No. 333-181971 Registration No. 333-181973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
December 18, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 Post-Effective Amendment No.1 to Form S-8 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100556 Registration No. 333-07361 Registration No. 333-121021 Registration No. 333-135184 Registration No. 333-135185 Registration No. 333-154573 Registration No. 333-181971 Registration No. 333-181973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
December 18, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 Post-Effective Amendment No.1 to Form S-8 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100556 Registration No. 333-07361 Registration No. 333-121021 Registration No. 333-135184 Registration No. 333-135185 Registration No. 333-154573 Registration No. 333-181971 Registration No. 333-181973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
December 18, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 Post-Effective Amendment No.1 to Form S-8 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100556 Registration No. 333-07361 Registration No. 333-121021 Registration No. 333-135184 Registration No. 333-135185 Registration No. 333-154573 Registration No. 333-181971 Registration No. 333-181973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
December 18, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 Post-Effective Amendment No.1 to Form S-8 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100556 Registration No. 333-07361 Registration No. 333-121021 Registration No. 333-135184 Registration No. 333-135185 Registration No. 333-154573 Registration No. 333-181971 Registration No. 333-181973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
December 18, 2013	S-8 POS	- POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-8 Post-Effective Amendment No.1 to Form S-8 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100556 Registration No. 333-07361 Registration No. 333-121021 Registration No. 333-135184 Registration No. 333-135185 Registration No. 333-154573 Registration No. 333-181971 Registration No. 333-181973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
December 18, 2013	S-8 POS	- POST EFFECTIVE AMENDMENT NO.1 TO FORM S-8 Post Effective Amendment No.1 to Form S-8 As filed with the Securities and Exchange Commission on December 18, 2013 Registration No. 333-100556 Registration No. 333-07361 Registration No. 333-121021 Registration No. 333-135184 Registration No. 333-135185 Registration No. 333-154573 Registration No. 333-181971 Registration No. 333-181973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,
December 13, 2013	EX-99.1	PERRIGO COMPANY AND ELAN CORPORATION PLC RECEIVE IRISH HIGH COURT APPROVAL FOR PERRIGO’S PROPOSED ACQUISITION OF ELAN EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE PERRIGO COMPANY AND ELAN CORPORATION PLC RECEIVE IRISH HIGH COURT APPROVAL FOR PERRIGO’S PROPOSED ACQUISITION OF ELAN ALLEGAN, MI and DUBLIN, IRELAND – December 13, 2013 – Perrigo Company (NYSE: PRGO; TASE) and Elan Corporation, plc (NYSE: ELN) (“Elan”) today announced that the Irish High Court has approved Perrigo’s pending acquisition of Elan. As previo
December 13, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (A
November 18, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (A
November 18, 2013	EX-99.1	Elan Announces Shareholder Approval of its Acquisition by Perrigo Company EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt Ph: +44-786-036-1746 Jamie Tully Ph: +1-212-687-8080 Elan Announces Shareholder Approval of its Acquisition by Perrigo Company DUBLIN—(BUSINESS WIRE)—November 18, 2013—The shareholders of Elan Corporation
November 12, 2013	425	Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2013 PERRIGO COMPANY LIMITED (Exact name of registrant as specified in its charter) Ireland 333-190859 Not Applicable (State of other Jurisdiction of Incorporatio
November 12, 2013	EX-4.2	REGISTRATION RIGHTS AGREEMENT EX-4.2 Exhibit 4.2 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into on November 8, 2013, among Perrigo Company Limited, a limited company organized under the laws of Ireland (the“Company”), which will be re-registered as a public limited company and renamed Perrigo Company plc at or prior to the effective time of the Acq
November 12, 2013	EX-4.1	PERRIGO COMPANY LIMITED (to be re-registered as a public limited company and renamed PERRIGO COMPANY PLC) THE GUARANTORS PARTY HERETO FROM TIME TO TIME WELLS FARGO BANK, NATIONAL ASSOCIATION, Dated as of November 8, 2013 1.30% Senior Notes due 2016 2 EX-4.1 2 d625796dex41.htm EX-4.1 Exhibit 4.1 PERRIGO COMPANY LIMITED (to be re-registered as a public limited company and renamed PERRIGO COMPANY PLC) AND THE GUARANTORS PARTY HERETO FROM TIME TO TIME TO WELLS FARGO BANK, NATIONAL ASSOCIATION, Trustee Indenture Dated as of November 8, 2013 1.30% Senior Notes due 2016 2.30% Senior Notes due 2018 4.00% Senior Notes due 2023 5.30% Senior Notes due 20
November 6, 2013	EX-99.1	PERRIGO COMPANY COMPENSATION COMMITTEE CHARTER EX-99.1 Exhibit 99.1 PERRIGO COMPANY COMPENSATION COMMITTEE CHARTER Purpose The purpose of the Compensation Committee is to carry out the Board of Directors’ overall responsibility relating to compensation of the directors and officers of Perrigo Company (the “Company”). Composition of the Committee The Committee shall consist of a minimum of three directors all of whom shall meet the independence
November 6, 2013	425	Merger Prospectus - COMBO FORM 8-K/425 425 1 d626525d8k.htm COMBO FORM 8-K/425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2013 PERRIGO COMPANY (Exact name of registrant as specified in its charter) MICHIGAN 001-09689 38-2799573 (State of other (Commissi
November 5, 2013	425	Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2013 PERRIGO COMPANY LIMITED (Exact name of registrant as specified in its charter) Ireland 333-190859 Not Applicable (State of other Jurisdiction of Incorporatio
November 5, 2013	EX-99.1	Perrigo Company Limited Announces Offering of $2,300,000,000 Senior Notes EX-99.1 Exhibit 99.1 Perrigo Company Limited Announces Offering of $2,300,000,000 Senior Notes ALLEGAN, MICHIGAN, November 5, 2013 /PRNewswire/ – Perrigo Company Limited, a limited company incorporated under the laws of Ireland (“Issuer”), announced that it has commenced an offering of Senior Notes due 2016, Senior Notes due 2018, Senior Notes due 2023 and Senior Notes due 2043, in an aggregate pr
November 5, 2013	EX-99.1	Perrigo Company Announces Tender Offer and Consent Solicitation for its 2.950% Notes due 2023 EX-99.1 2 d623402dex991.htm EX-99.1 Exhibit 99.1 Perrigo Company Announces Tender Offer and Consent Solicitation for its 2.950% Notes due 2023 ALLEGAN, Mich., November 5, 2013 /PRNewswire/ – Perrigo Company (NYSE, TASE: PRGO) today announced that it is commencing a tender offer to purchase any and all of its outstanding $600 million in aggregate principal amount of 2.950% notes due 2023 (CUSIP No.
November 5, 2013	EX-99.2	Perrigo Company Limited Announces Pricing of $2,300,000,000 Senior Notes EX-99.2 Exhibit 99.2 Perrigo Company Limited Announces Pricing of $2,300,000,000 Senior Notes ALLEGAN, MICHIGAN/DUBLIN, IRELAND, November 5, 2013 /PRNewswire/ – Perrigo Company Limited, a limited company incorporated under the laws of Ireland (“Issuer”), announced that it has priced an offering of $2,300,000,000 aggregate principal amount of senior notes, consisting of $500,000,000 aggregate princ
November 5, 2013	425	Merger Prospectus - 8-K 425 1 d623402d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2013 PERRIGO COMPANY (Exact name of registrant as specified in its charter) MICHIGAN 001-09689 38-2799573 (State of other Jurisdiction of Incorpor
October 31, 2013	EX-99.1	Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins - Fiscal first quarter net sales of $933 million, up 21%.
October 31, 2013	425	Merger Prospectus - 425 425 1 v358822425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2013 PERRIGO COMPANY (Exact name of registrant as specified in its charter) MICHIGAN 0-19725 38-2799573 (State of other (Commission (IRS Employer
October 24, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of
October 24, 2013	EX-99.1	Elan Corporation, plc Unaudited Condensed Consolidated Financial Statements Three and Nine Month Periods Ended September 30, 2013 EX-99.1 Table of Contents Exhibit 99.1 Elan Corporation, plc Unaudited Condensed Consolidated Financial Statements Three and Nine Month Periods Ended September 30, 2013 Table of Contents Table of Contents Page Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2013 and 2012 2 Unaudited Condensed Consolidated Statements of Comprehensive Incom
October 24, 2013	EX-99.1	ELAN REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph: 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt Ph: +44-786-036-1746 Jamie Tully Ph: +1-212-687-8080 ELAN REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Dublin, Ireland, October 24, 2013 - Elan Corporation, plc (NYSE:ELN) today reported its third quarter and fir
October 24, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Ad
October 15, 2013	425	Merger Prospectus - 425 425 Filed by Perrigo Company pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Elan Corporation, plc Commission File No.
October 15, 2013	425	Merger Prospectus - 425 Filed by Perrigo Company pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Elan Corporation, plc Commission File No.
October 10, 2013	EX-99.1	Elan Announces Webcast of Third Quarter 2013 Financial Results EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt Ph: +44-786-036-1746 Jamie Tully Ph: +1-212-687-8080 Elan Announces Webcast of Third Quarter 2013 Financial Results DUBLIN, IRELAND, October 10, 2013 - Elan Corporation, plc (NYSE: ELN) announced today that it wi
October 10, 2013	425	Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2013 PERRIGO COMPANY (Exact name of registrant as specified in its charter) MICHIGAN 0-19725 38-2799573 (State of other Jurisdiction of Incorporation) (Commission
October 10, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of
October 10, 2013	EX-99.1	PERRIGO COMPANY ANNOUNCES DATE OF SPECIAL SHAREHOLDER MEETING IN CONNECTION WITH ACQUISITION OF ELAN CORPORATION, PLC EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE PERRIGO COMPANY ANNOUNCES DATE OF SPECIAL SHAREHOLDER MEETING IN CONNECTION WITH ACQUISITION OF ELAN CORPORATION, PLC Allegan, Mich. – October 9, 2013 – Perrigo Company (NYSE, TASE: PRGO) today announced that it has that it has scheduled a shareholder meeting for Monday, November 18, 2013 in connection with Perrigo’s proposed previously announced acquisit
September 30, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address o
September 30, 2013	425	Merger Prospectus - 425 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934.
September 30, 2013	EX-99.1	1 EX-99.1 2 d605205dex991.htm EX-99.1 Exhibit 99.1 30 September 2013 Elan announces dates of shareholder meetings in connection with scheme of arrangement. Elan Corporation, plc. (NYSE:ELN) (“Elan”) today announced that it has scheduled shareholder meetings for Monday, November 18, 2013 in connection with Perrigo Company’s (NYSE, TASE: PRGO) (“Perrigo”) proposed acquisition of Elan. As previously an
September 4, 2013	EX-99.1	Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome Exhibit 99.1 Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt Ph: +44-786-036-1746 Jamie Tully Ph: +1-212-687-8080 Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome DUBLIN, IRELAND, September 3, 2013 - Elan Corporation, plc (NYSE: ELN) announc
September 4, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address o
August 28, 2013	EX-99.1	PERRIGO FILES REGISTRATION STATEMENT ON FORM S-4 IN CONNECTION WITH PROPOSED ACQUISITION OF ELAN EX-99.1 Exhibit 99.1 PERRIGO FILES REGISTRATION STATEMENT ON FORM S-4 IN CONNECTION WITH PROPOSED ACQUISITION OF ELAN Allegan, Michigan and Dublin, Ireland — (28 August 2013) — Perrigo Company (NYSE, TASE: PRGO) (“Perrigo”) and Elan Corporation, plc. (NYSE: ELN) (“Elan”) today announced that Perrigo Company Limited (“New Perrigo”) has filed with the U.S. Securities and Exchange Commission (SEC) a
August 28, 2013	425	Merger Prospectus - 425 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934.
August 28, 2013	6-K	Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address
August 28, 2013	425	Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2013 PERRIGO COMPANY (Exact name of registrant as specified in its charter) MICHIGAN 0-19725 38-2799573 (State of other Jurisdiction of Incorporation) (Commission File Numb
August 28, 2013	EX-99.1	PERRIGO FILES REGISTRATION STATEMENT ON FORM S-4 IN CONNECTION WITH PROPOSED ACQUISITION OF ELAN EX-99.1 Exhibit 99.1 PERRIGO FILES REGISTRATION STATEMENT ON FORM S-4 IN CONNECTION WITH PROPOSED ACQUISITION OF ELAN Allegan, Michigan and Dublin, Ireland — (28 August 2013) — Perrigo Company (NYSE, TASE: PRGO) (“Perrigo”) and Elan Corporation, plc. (NYSE: ELN) (“Elan”) today announced that Perrigo Company Limited (“New Perrigo”) has filed with the U.S. Securities and Exchange Commission (SEC) a
August 28, 2013	425	Merger Prospectus - 425 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filer: Perrigo Company Subject Company: Elan Corporation, plc Commission File No.
August 20, 2013	EX-99.1	Elan Corporation, plc Unaudited Condensed Consolidated Financial Statements Six Month Period Ended June 30, 2013 EX-99.1 Exhibit 99.1 Elan Corporation, plc Unaudited Condensed Consolidated Financial Statements Six Month Period Ended June 30, 2013 Table of Contents Page Unaudited Condensed Consolidated Statements of Operations for the six months ended June 30, 2013 and 2012 2 Unaudited Condensed Consolidated Statements of Comprehensive Income for the six months ended June 30, 2013 and 2012 3 Unaudited Condens
August 20, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Add
August 16, 2013	425	Merger Prospectus - 425 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filer: Perrigo Company Subject Company: Elan Corporation, plc Commission File No.
August 16, 2013	425	Merger Prospectus - 425 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filer: Perrigo Company Subject Company: Elan Corporation, plc Commission File No.
August 15, 2013	425	Merger Prospectus - 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filer: Perrigo Company Subject Company: Elan Corporation, plc Commission File No.
August 15, 2013	EX-99.1	PERRIGO REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR REVENUE AND EARNINGS EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE PERRIGO REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR REVENUE AND EARNINGS • Fiscal fourth quarter net sales increased $135 million, or 16%, to $967 million. • GAAP income in the fourth quarter increased 11% to $118 million, or $1.25 per diluted share and adjusted income increased 22% to $148 million, or $1.57 per diluted share. • Fiscal 2013 net sales in
August 15, 2013	425	Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2013 PERRIGO COMPANY (Exact name of registrant as specified in its charter) MICHIGAN 0-19725 38-2799573 (State of other Jurisdiction of Incorporation) (Commission
August 2, 2013	SC 13G	LPCN / Lipocine Inc. / ELAN CORP PLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lipocine Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 53630X 10 4 (CUSIP Number) July 24, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
August 2, 2013	425	Merger Prospectus - 425 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filer: Perrigo Company Subject Company: Elan Corporation, plc Commission File No.
July 31, 2013	425	Merger Prospectus - 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filer: Perrigo Company Subject Company: Elan Corporation, plc Commission File No.
July 30, 2013	EX-99.3	Quality Affordable Healthcare Products™ July 31, 2013 Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company Exhibit 99.3 Quality Affordable Healthcare Products™ July 31, 2013 Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company Quality Affordable Healthcare Products™ 2 Important Information For Investors And Shareholders This announcement does not constitute an offer to sell, or an invitation to subscribe for or purchase or purchase or exchange , any securities or the solicitation
July 30, 2013	EX-99.1	PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY Exhibit 99.1 29 July 2013 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY · Establishes a differentiated platform for fu
July 30, 2013	425	Merger Prospectus - 425 Filed Pursuant to Rule 425 of the Securities Act of 1993, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934.
July 30, 2013	EX-99.2	PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY Exhibit 99.2 29 July 2013 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY · Establishes a differentiated platform for fu
July 30, 2013	EX-99.1	TAKEOVER PANEL DEROGATION UNDER RULE 30.2 EX-99.1 2 d576423dex991.htm EX-99.1 Exhibit 99.1 TAKEOVER PANEL DEROGATION UNDER RULE 30.2 Allegan, Michigan and Dublin, Ireland — (30 July 2013) — Perrigo Company (NYSE: PRGO), a leading global provider of quality, affordable healthcare products (“Perrigo”) and Elan Corporation, plc (NYSE: ELN) (“Elan”), a leading biotechnology company headquartered in Ireland, today announced that the Irish Take
July 30, 2013	EX-99.3	Quality Affordable Healthcare Products™ July 31, 2013 Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company Exhibit 99.3 Quality Affordable Healthcare Products™ July 31, 2013 Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company Quality Affordable Healthcare Products™ 2 Important Information For Investors And Shareholders This announcement does not constitute an offer to sell, or an invitation to subscribe for or purchase or purchase or exchange , any securities or the solicitation
July 30, 2013	EX-99.5	Dated 28 July 2013 ELAN CORPORATION, PLC PERRIGO COMPANY EXPENSES REIMBURSEMENT AGREEMENT A&L Goodbody Exhibit 99.5 EXECUTION VERSION Dated 28 July 2013 ELAN CORPORATION, PLC and PERRIGO COMPANY EXPENSES REIMBURSEMENT AGREEMENT A&L Goodbody THIS AGREEMENT is made as a deed on 28 July, 2013 BETWEEN: (1) ELAN CORPORATION, PLC, a public limited company incorporated in Ireland (registered number 30356), with registered office at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (hereinafte
July 30, 2013	EX-99.2	PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY Exhibit 99.2 29 July 2013 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY · Establishes a differentiated platform for fu
July 30, 2013	EX-99.6	EVENT DATE/TIME: JULY 29, 2013 / 12:30PM GMT Exhibit 99.6 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT PRGO - Perrigo Co to Acquire Elan Corporation PLC Conference Call EVENT DATE/TIME: JULY 29, 2013 / 12:30PM GMT OVERVIEW: On 07/29/13, DRX.I reported that Perrigo Company and Co. have entered into a definitive agreement, under which Co. will be acquired by new holding co. incorporated in Ireland. Cash and stock transaction is valued at app
July 30, 2013	EX-99.6	EVENT DATE/TIME: JULY 29, 2013 / 12:30PM GMT Exhibit 99.6 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT PRGO - Perrigo Co to Acquire Elan Corporation PLC Conference Call EVENT DATE/TIME: JULY 29, 2013 / 12:30PM GMT OVERVIEW: On 07/29/13, DRX.I reported that Perrigo Company and Co. have entered into a definitive agreement, under which Co. will be acquired by new holding co. incorporated in Ireland. Cash and stock transaction is valued at app
July 30, 2013	EX-99.1	PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY EX-99.1 2 t1300215ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 29 July 2013 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY · Es
July 30, 2013	EX-99.4	Investor, Analyst and Media FAQ Exhibit 99.4 Investor, Analyst and Media FAQ STRATEGIC RATIONALE 1. What is the strategic rationale for the transaction? This transaction combines two great companies to create value for our respective shareholders, patients and customers and will create a global healthcare company with an industry-leading growth profile and the geographic scale and scope to continue building a truly differentiate
July 30, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Addre
July 30, 2013	EX-99.5	Dated 28 July 2013 ELAN CORPORATION, PLC PERRIGO COMPANY EXPENSES REIMBURSEMENT AGREEMENT A&L Goodbody EX-99.5 6 t1300214ex99-5.htm EXHIBIT 99.5 Exhibit 99.5 EXECUTION VERSION Dated 28 July 2013 ELAN CORPORATION, PLC and PERRIGO COMPANY EXPENSES REIMBURSEMENT AGREEMENT A&L Goodbody THIS AGREEMENT is made as a deed on 28 July, 2013 BETWEEN: (1) ELAN CORPORATION, PLC, a public limited company incorporated in Ireland (registered number 30356), with registered office at Treasury Building, Lower Grand C
July 30, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
July 30, 2013	425	Merger Prospectus - 425 425 Filed Pursuant to Rule 425 of the Securities Act of 1933, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934.
July 30, 2013	EX-99.1	TAKEOVER PANEL DEROGATION UNDER RULE 30.2 EX-99.1 2 d576423dex991.htm EX-99.1 Exhibit 99.1 TAKEOVER PANEL DEROGATION UNDER RULE 30.2 Allegan, Michigan and Dublin, Ireland — (30 July 2013) — Perrigo Company (NYSE: PRGO), a leading global provider of quality, affordable healthcare products (“Perrigo”) and Elan Corporation, plc (NYSE: ELN) (“Elan”), a leading biotechnology company headquartered in Ireland, today announced that the Irish Take
July 30, 2013	EX-99.4	Investor, Analyst and Media FAQ Exhibit 99.4 Investor, Analyst and Media FAQ STRATEGIC RATIONALE 1. What is the strategic rationale for the transaction? This transaction combines two great companies to create value for our respective shareholders, patients and customers and will create a global healthcare company with an industry-leading growth profile and the geographic scale and scope to continue building a truly differentiate
July 29, 2013	EX-99.1	PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY EX-99.1 7 d574739dex991.htm EX-99.1 Exhibit 99.1 29 July 2013 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY • Establis
July 29, 2013	EX-2.2	APPENDIX I CONDITIONS OF THE ACQUISITION AND THE SCHEME Part A EX-2.2 Exhibit 2.2 APPENDIX I CONDITIONS OF THE ACQUISITION AND THE SCHEME Part A The Acquisition and Scheme will comply with the Takeover Rules and, where relevant, the rules and regulations of the Exchange Act and the rules and regulations of NYSE and are subject to the terms and conditions set out in this document. The Acquisition and Scheme are governed by the Laws of Ireland and subject to th
July 29, 2013	425	Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2013 PERRIGO COMPANY (Exact Name of Registrant as Specified in Charter) MICHIGAN 0-19725 38-2799573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
July 29, 2013	EX-10.2	CASH BRIDGE CREDIT AGREEMENT dated as of July 28, 2013 BLISFONT LIMITED, as Borrower, THE LENDERS PARTY HERETO, HSBC BANK USA, N.A., as Syndication Agent BARCLAYS BANK PLC, as Administrative Agent, BARCLAYS BANK PLC HSBC SECURITIES (USA) INC. as Join EX-10.2 6 d574739dex102.htm EX-10.2 Exhibit 10.2 CASH BRIDGE CREDIT AGREEMENT dated as of July 28, 2013 among BLISFONT LIMITED, as Borrower, THE LENDERS PARTY HERETO, HSBC BANK USA, N.A., as Syndication Agent and BARCLAYS BANK PLC, as Administrative Agent, BARCLAYS BANK PLC and HSBC SECURITIES (USA) INC. as Joint Lead Arrangers and Joint Bookrunners Table of Contents Page ARTICLE I Definitions 1 S
July 29, 2013	EX-99.2	Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company EX-99.2 Exhibit 99.2 Quality Affordable Healthcare Products™ Perrigo Company to Acquire Elan to Create Premier Global Healthcare Company Important Information For Investors And Shareholders This document does not constitute an offer to sell, or an invitation to subscribe for or purchase or purchase or exchange, any securities or the solicitation of any vote or approval in any jurisdiction, nor sha
July 29, 2013	EX-99.6	Inside Perrigo Article EX-99.6 12 d574739dex996.htm EX-99.6 Exhibit 99.6 Inside Perrigo Article Today we are announcing that Perrigo and Elan, a life sciences company based in Ireland, have entered into a definitive agreement under which Elan will be acquired by a new holding company incorporated in Ireland. The transaction brings together two great companies to create value for our respective patients, customers and sh
July 29, 2013	EX-99.1	PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY EX-99.1 Exhibit 99.1 29 July 2013 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PERRIGO COMPANY TO ACQUIRE ELAN CORPORATION, PLC FOR US$8.6 BILLION, ESTABLISHING PREMIER GLOBAL HEALTHCARE COMPANY • Establishes a differentiated platfor
July 29, 2013	EX-10.1	DEBT BRIDGE CREDIT AGREEMENT dated as of July 28, 2013 BLISFONT LIMITED, as Borrower, THE LENDERS PARTY HERETO, HSBC BANK USA, N.A., as Syndication Agent BARCLAYS BANK PLC, as Administrative Agent, BARCLAYS BANK PLC HSBC SECURITIES (USA) INC. as Join EX-10.1 5 d574739dex101.htm EX-10.1 Exhibit 10.1 DEBT BRIDGE CREDIT AGREEMENT dated as of July 28, 2013 among BLISFONT LIMITED, as Borrower, THE LENDERS PARTY HERETO, HSBC BANK USA, N.A., as Syndication Agent and BARCLAYS BANK PLC, as Administrative Agent, BARCLAYS BANK PLC and HSBC SECURITIES (USA) INC. as Joint Lead Arrangers and Joint Bookrunners Table of Contents Page ARTICLE I Definitions 1 S
July 29, 2013	EX-2.1	EX-2.1
July 29, 2013	EX-99.4	Employee Letter EX-99.4 10 d574739dex994.htm EX-99.4 Exhibit 99.4 Employee Letter I am pleased to share with you that Perrigo and the life sciences company Elan have entered into a definitive agreement under which Elan will be acquired by a new holding company incorporated in Ireland. The cash and stock transaction is valued at approximately US$8.6 billion. The transaction brings together two great companies to c
July 29, 2013	EX-99.7	2 EX-99.7 13 d574739dex997.htm EX-99.7 Exhibit 99.7 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT PRGO—Perrigo Co to Acquire Elan Corporation PLC Conference Call EVENT DATE/TIME: JULY 29, 2013 / 12:30PM GMT OVERVIEW: On 07/29/13, DRX.I reported that Perrigo Company and Co. have entered into a definitive agreement, under which Co. will be acquired by new holding co. incorporated in Ireland. Cash and
July 29, 2013	EX-99.5	Perrigo Employee Frequently Asked Questions (FAQ) EX-99.5 Exhibit 99.5 Perrigo Employee Frequently Asked Questions (FAQ) 1. What is the strategic rationale for the transaction? The transaction brings together two great companies to create value for our respective patients, customers and shareholders. The combination creates a global healthcare company with an industry-leading growth profile and the scale and scope to continue building a truly dif
July 29, 2013	425	Merger Prospectus - FORM 8-K 425 1 d574739d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2013 PERRIGO COMPANY (Exact Name of Registrant as Specified in Charter) MICHIGAN 0-19725 38-2799573 (State or Other Jurisdiction of Incorporatio
July 29, 2013	EX-2.3	Dated 28 July 2013 ELAN CORPORATION, PLC PERRIGO COMPANY EXPENSES REIMBURSEMENT AGREEMENT A&L Goodbody EX-2.3 Exhibit 2.3 Dated 28 July 2013 ELAN CORPORATION, PLC and PERRIGO COMPANY EXPENSES REIMBURSEMENT AGREEMENT A&L Goodbody THIS AGREEMENT is made as a deed on 28 July, 2013 BETWEEN: (1) ELAN CORPORATION, PLC, a public limited company incorporated in Ireland (registered number 30356), with registered office at Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (hereinafter called “El
July 29, 2013	EX-99.3	Investor, Analyst and Media FAQ EX-99.3 9 d574739dex993.htm EX-99.3 Exhibit 99.3 Investor, Analyst and Media FAQ STRATEGIC RATIONALE 1. What is the strategic rationale for the transaction? This transaction combines two great companies to create value for our respective shareholders, patients and customers and will create a global healthcare company with an industry-leading growth profile and the geographic scale and scope to con
July 25, 2013	EX-99.1	Elan Corporation, plc Half-Year Financial Report Six Months Ended 30 June 2013 EX-99.1 Table of Contents Exhibit 99.1 Elan Corporation, plc Half-Year Financial Report Six Months Ended 30 June 2013 Table of Contents Table of Contents Page(s) Half-Year Management Report 1 Unaudited Condensed Consolidated Half-Year Financial Statements 16 Notes to the Unaudited Condensed Consolidated Half-Year Financial Statements 21 U.S. GAAP Information 46 Responsibility Statement 57 Independ
July 25, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2013 Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address
July 24, 2013	EX-99.1	ELAN REPORTS SECOND QUARTER AND FIRST HALF 2013 FINANCIAL RESULTS EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph: 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt Ph: +44-786-036-1746 Jamie Tully Ph: +1-212-687-8080 ELAN REPORTS SECOND QUARTER AND FIRST HALF 2013 FINANCIAL RESULTS Dublin, Ireland, July 24, 2013 - Elan Corporation, plc (NYSE:ELN) today reported its second q
July 24, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
July 17, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
July 17, 2013	EX-99.1	FDA Grant Fast Track Designation to ELND005 for the Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt Ph: +44-786-036-1746 Jamie Tully Ph: +1-212-687-8080 FDA Grant Fast Track Designation to ELND005 for the Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease DUBLIN, IRELAND, July 17, 2013 - Elan Corpora
July 10, 2013	EX-99.1	Elan Announces Webcast of Second Quarter 2013 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt Ph: +44-786-036-1746 Jamie Tully Ph: +1-212-687-8080 Elan Announces Webcast of Second Quarter 2013 Financial Results DUBLIN, IRELAND, July 10, 2013 - Elan Corporation, plc (NYSE: ELN) announced today that it will
July 10, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 28, 2013	EX-12.2	CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EX-12.2 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nigel Clerkin, certify that: 1. I have reviewed this annual report on Form 20-F/A of Elan Corporation, plc (the Company). 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
June 28, 2013	EX-13.2	Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EX-13.2 Exhibit 13.2 Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F/A for the period ending December 31, 2012 (the “Report”) of Elan Corporation, plc (the Company), as filed with the Securities and Exchange Commission on the date hereof, I, Nigel Clerkin, Executive Vice Preside
June 28, 2013	20-F/A	- FORM 20-F/A 20-F/A 1 d549969d20fa.htm FORM 20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F/A (Amendment No. 1) (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2012 OR ¨ TRANSITION RE
June 28, 2013	EX-13.1	Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EX-13.1 Exhibit 13.1 Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F/A for the period ending December 31, 2012 (the “Report”) of Elan Corporation, plc (the Company), as filed with the Securities and Exchange Commission on the date hereof, I, G. Kelly Martin, Chief Executive Offi
June 28, 2013	EX-12.1	CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 EX-12.1 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, G. Kelly Martin, certify that: 1. I have reviewed this annual report on Form 20-F/A of Elan Corporation, plc (the Company). 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t
June 18, 2013	EX-99.(A)(26)	Elan Advises Shareholders to withdraw any acceptances of the Royalty Pharma Offer and not to tender any further acceptances into this lapsed offer* EX-99.(A)(26) 2 t1300163exha26.htm EXHIBIT (A)(26) Exhibit (a)(26) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Advises Shareholders to withdraw any acceptances of the Royalty
June 18, 2013	EX-99.A1PPPP	ROYALTY PHARMA ANNOUNCES WITHDRAWAL OF JUDICIAL REVIEW AND LAPSE OF OFFER (a)(1)(PPPP) FOR IMMEDIATE RELEASE ROYALTY PHARMA ANNOUNCES WITHDRAWAL OF JUDICIAL REVIEW AND LAPSE OF OFFER New York – June 18, 2013 – Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel’s decision requiring it to lapse its offer for Elan Corporation, plc (NYSE: ELN) if, among other things, Elan shareholders approved the Share Repurchase Program.
June 18, 2013	SC TO-T/A	- FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 17 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL ECHO ACQUISITION LUX TWO SARL ECHO ACQUISITIO
June 18, 2013	EX-99.1	ELAN ADVISES SHAREHOLDERS TO WITHDRAW ANY ACCEPTANCES OF THE ROYALTY PHARMA OFFER AND NOT TO TENDER ANY FURTHER ACCEPTANCES INTO THIS LAPSED OFFER* EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN ADVISES SHAREHOLDERS TO WITHDRAW ANY ACCEPTANCES OF THE ROYALTY PHARMA OFFER AND NOT TO TENDER ANY FURTHER ACCEPTANCES
June 18, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K 6-K 1 t13001666k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dub
June 18, 2013	EX-99.A1OOOO	1 EX-99.A1OOOO 2 dp38975ex-a1oooo.htm EXHIBIT (A)(1)(OOOO) (a)(1)(OOOO) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE ROYALTY PHARMA ANNOUNCES WITHDRAWAL OF JUDICIAL REVIEW AND LAPSE OF OFFER 18 June 2013 New York – June 18,
June 18, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER 6-K 1 el20130618-6k.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lo
June 18, 2013	SC 14D9/A	- AMENDMENT NO. 15 TO SCHEDULE 14D-9 SC 14D9/A 1 t1300163sc14d9.htm AMENDMENT NO. 15 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D−9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 15) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.0
June 18, 2013	EX-99.(A)(27)	Elan Corporation, plc Extraordinary General Meeting 17 June 2013 Poll Results by Resolution EX-99.(A)(27) 3 t1300163exha27.htm EXHIBIT (A)(27) Exhibit (a)(27) Elan Corporation, plc Extraordinary General Meeting 17 June 2013 Poll Results by Resolution No. Resolution Total Voted Vote For Vote Against Vote Withheld(1) 1 THAT the entry by the Company into the Theravance Transaction, (as described and defined in the circular to Elan Shareholders dated 27 May 2013 of which this Notice forms pa
June 17, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 17, 2013	SC TO-T/A	- FORM SC TO-T/A SC TO-T/A 1 dp38974sctota-a16.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 16 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE S
June 17, 2013	EX-99.A1KKKK	Royalty Pharma Chairman Writes Open Letter to Elan Board Expresses Disappointment at Elan’s Unwillingness to Negotiate Improved Terms in a Recommended Transaction Structured as a Scheme of Arrangement EX-99.A1KKKK 2 dp38974ex-a1kkkk.htm EXHIBIT (A)(1)(KKKK) Exhibit (a)(1)(KKKK) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE Royalty Pharma Chairman Writes Open Letter to Elan Board Expresses Disappointment at Elan’s Unwill
June 17, 2013	EX-99.(A)(25)	Elan announces RESULTS OF EGM Exhibit (a)(25) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan announces RESULTS OF EGM - share repurchase resolution approved - Royalty Pharma hostile bid lapses IN ACCORDANCE WITH ITS TERMS Dublin, Ireland - June 17, 2013 - Elan Corporation, plc (NYSE: ELN) (Elan or the Company) announces that, at its Extraordinary General Meeting held earlier today, shareholders approved the Share Repurchase Program.
June 17, 2013	EX-99.A1MMMM	NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION EX-99.A1MMMM 4 dp38974ex-a1mmmm.htm EXHIBIT (A)(1)(MMMM) Exhibit (a)(1)(MMMM) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE ROYALTY PHARMA INFORMS ELAN STOCKHOLDERS ABOUT THE CONSEQUENCES ARISING FROM THE RESULTS OF THE EL
June 17, 2013	EX-99.A1NNNN	ROYALTY PHARMA INFORMS ELAN STOCKHOLDERS ABOUT THE CONSEQUENCES ARISING FROM THE RESULTS OF THE ELAN EGM EARLIER TODAY EX-99.A1NNNN 5 dp38974ex-a1nnnn.htm EXHIBIT (A)(1)(NNNN) Exhibit (a)(1)(NNNN) FOR IMMEDIATE RELEASE ROYALTY PHARMA INFORMS ELAN STOCKHOLDERS ABOUT THE CONSEQUENCES ARISING FROM THE RESULTS OF THE ELAN EGM EARLIER TODAY NEW YORK- June 17, 2013- As the Share Repurchase Resolution has been passed at the Elan EGM earlier today, Royalty Pharma’s Offer for Elan Corporation, plc (NYSE: ELN) has lapsed in
June 17, 2013	EX-99.A1LLLL	Royalty Pharma Chairman Writes Open Letter to Elan Board Expresses Disappointment at Elan’s Unwillingness to Negotiate Improved Terms in a Recommended Transaction Structured as a Scheme of Arrangement Exhibit (a)(1)(LLLL) Royalty Pharma Chairman Writes Open Letter to Elan Board Expresses Disappointment at Elan’s Unwillingness to Negotiate Improved Terms in a Recommended Transaction Structured as a Scheme of Arrangement New York – June 17, 2013 – Royalty Pharma announced today that Rory Riggs, Chairman and Co-Founder of the Royalty Pharma group, is sending the following open letter to the Board of Directors of Elan Corporation, plc (NYSE:ELN): To the Board of Directors of Elan Corporation: As you know, Elan’s shareholders appear poised to decisively reject the Theravance Transaction and AOP Transaction at today’s EGM*.
June 17, 2013	EX-99.1	ELAN ANNOUNCES RESULTS OF EGM EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN ANNOUNCES RESULTS OF EGM - SHARE REPURCHASE RESOLUTION APPROVED - ROYALTY PHARMA HOSTILE BID LAPSES IN ACCORDANCE WITH
June 17, 2013	SC 14D9/A	- AMENDMENT NO. 14 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D−9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 14) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05 each (Title of Class of Securities) G29539106 (CUSIP Number of C
June 14, 2013	SC 14D9/A	- AMENDMENT NO. 13 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D−9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 13) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05 each (Title of Class of Securities) G29539106 (CUSIP Number of C
June 14, 2013	EX-99.(A)(1)(IIII)	Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty Ordinary Shareholders Urged to Vote AGAINST All Four Proposals Today to Allow Royalty Pharma's Offer of $13 per Share Plus an up to $2.50 CVR to Move Forward Royalty Pharma Beli EX-99.(A)(1)(IIII) 5 dp38967ex-a1iiii.htm EXHIBIT (A)(1)(IIII) Exhibit (a)(1)(IIII) Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty Ordinary Shareholders Urged to Vote AGAINST All Four Proposals Today to Allow Royalty Pharma's Offer of $13 per Share Plus an up to $2.50 CVR to Move Forward Royalty Pharma Believes Sudden Sales Process Announced by Elan Friday, After Not Enga
June 14, 2013	EX-99.(A)(1)(JJJJ)	Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty Ordinary Shareholders Urged to Vote AGAINST All Four Proposals Today to Allow Royalty Pharma’s Offer of $13 per Share Plus an up to $2.50 CVR to Move Forward Royalty Pharma Beli EX-99.(A)(1)(JJJJ) 6 dp38967ex-a1jjjj.htm EXHIBIT (A)(1)(JJJJ) Exhibit (a)(1)(JJJJ) Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty Ordinary Shareholders Urged to Vote AGAINST All Four Proposals Today to Allow Royalty Pharma’s Offer of $13 per Share Plus an up to $2.50 CVR to Move Forward Royalty Pharma Believes Sudden Sales Process Announced by Elan Friday, After Not Enga
June 14, 2013	EX-99.(A)(1)(HHHH)	ELAN ADS HOLDERS DECISIVELY VOTE AGAINST THERAVANCE AND AOP TRANSACTIONS VOTE OF ORDINARY SHAREHOLDERS MAY DETERMINE WHETHER ROYALTY PHARMA’S OFFER OF $13 IN CASH PLUS AN UP TO $2.50 CVR WILL BE PERMITTED TO PROCEED VOTE “AGAINST” ALL FOUR TRANSACTIO EX-99.(A)(1)(HHHH) 3 dp38967ex-a1hhhh.htm EXHIBIT (A)(1)(HHHH) Exhibit (a)(1)(HHHH) FOR IMMEDIATE RELEASE ELAN ADS HOLDERS DECISIVELY VOTE AGAINST THERAVANCE AND AOP TRANSACTIONS VOTE OF ORDINARY SHAREHOLDERS MAY DETERMINE WHETHER ROYALTY PHARMA’S OFFER OF $13 IN CASH PLUS AN UP TO $2.50 CVR WILL BE PERMITTED TO PROCEED VOTE “AGAINST” ALL FOUR TRANSACTIONS NEW YORK – June 14, 2013 - Royalty Pharma
June 14, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 14, 2013	EX-99.1	Elan To Proceed with Formal Sale Process Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan To Proceed with Formal Sale Process · Elan Board authorizes formal sale process to commence · Board and management are
June 14, 2013	EX-99.(A)(24)	Elan To Proceed with Formal Sale Process Exhibit (a)(24) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan To Proceed with Formal Sale Process · Elan Board authorizes formal sale process to commence · Board and management
June 14, 2013	SC TO-T/A	- SC TO-T/A15 SC TO-T/A 1 dp38967sctota-a15.htm SC TO-T/A15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 15 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL
June 14, 2013	EX-99.(A)(1)(GGGG)	ELAN ADS HOLDERS DECISIVELY VOTE AGAINST THERAVANCE AND AOP TRANSACTIONS VOTE OF ORDINARY SHAREHOLDERS MAY DETERMINE WHETHER ROYALTY PHARMA’S OFFER OF $13 IN CASH PLUS AN UP TO $2.50 CVR WILL BE PERMITTED TO PROCEED VOTE “AGAINST” ALL FOUR TRANSACTIO EX-99.(A)(1)(GGGG) 2 dp38967ex-a1gggg.htm EXHIBIT (A)(1)(GGGG) Exhibit (a)(1)(GGGG) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE ELAN ADS HOLDERS DECISIVELY VOTE AGAINST THERAVANCE AND AOP TRANSACTIONS VOTE OF ORDINARY SH
June 13, 2013	SC TO-T/A	- FORM SC TO-T/A SC TO-T/A 1 dp38939sctota-a14.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 14 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL ECHO ACQUISITION LU
June 13, 2013	EX-99.(A)(1)(FFFF)	ROYALTY PHARMA ANNOUNCES OFFER MAY LAPSE (BE WITHDRAWN) Exhibit (a)(1)(FFFF) ROYALTY PHARMA ANNOUNCES OFFER MAY LAPSE (BE WITHDRAWN) NEW YORK – JUNE 13, 2013 - Royalty Pharma today announces that as of 5:30 pm EDT on Wednesday, June 12, 2013 holders of approximately 276 million Elan ADSs (NYSE: ELN), representing more than 70% of the Elan ADSs held in street name, had voted on the Elan proposals.
June 13, 2013	144	- FORM 144 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.
June 13, 2013	EX-99.(A)(1)(EEEE)	ROYALTY PHARMA ANNOUNCES OFFER MAY LAPSE (BE WITHDRAWN) Exhibit (a)(1)(EEEE) ROYALTY PHARMA ANNOUNCES OFFER MAY LAPSE (BE WITHDRAWN) NEW YORK – JUNE 13, 2013 - Royalty Pharma today announces that as of 5:30 pm EDT on Wednesday, June 12, 2013 holders of approximately 276 million Elan ADSs (NYSE: ELN), representing more than 70% of the Elan ADSs held in street name, had voted on the Elan proposals.
June 12, 2013	EX-99.1	Unresolved SEC Comment EXHIBIT 99.1 Unresolved SEC Comment In accordance with the provisions of Irish Company Law, in 2012, Elan Corporation, plc (the “Company”) took steps to create income available for distribution. At our Annual General Meeting on May 24, 2012, our shareholders resolved, subject to the approval of the High Court of Ireland, to reduce the share premium account (“APIC”) of the Company by cancelling som
June 12, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant?s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 11, 2013	EX-99.(A)(1)(VVV)	NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Exhibit (a)(1)(VVV) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE Royalty Pharma Acceptances Announcement NEW YORK – June 11, 2013 – In accordance with Rule 17.
June 11, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER 6-K 1 el20130611-6k.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lo
June 11, 2013	SC 14D9/A	- AMENDMENT NO. 12 TO SCHEDULE 14D-9 SC 14D9/A 1 t1300131sc14d9a.htm AMENDMENT NO. 12 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 12) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.
June 11, 2013	EX-99.(A)(1)(WWW)	2 EX-99.(A)(1)(WWW) 4 dp38904ex-a1www.htm EXHIBIT (A)(1)(WWW) Exhibit (a)(1)(WWW) Royalty Pharma Acceptances Announcement NEW YORK – June 11, 2013 – In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited (“Royalty Pharma”) today announced acceptance levels of its Further Increased Offer for Elan Corporation, plc (N
June 11, 2013	EX-99.(A)(1)(DDDD)	ROYALTY PHARMA FILES JUDICIAL REVIEW PROCEEDINGS EX-99.(A)(1)(DDDD) 11 dp38904ex-a1dddd.htm EXHIBIT (A)(1)(DDDD) Exhibit (a)(1)(DDDD) ROYALTY PHARMA FILES JUDICIAL REVIEW PROCEEDINGS NEW YORK – JUNE 11, 2013 - Royalty Pharma today announces that it has reluctantly filed judicial review proceedings related to the decision of the Irish Takeover Panel requiring it to lapse its Further Increased Offer in the event that the ELND005 Transaction and /
June 11, 2013	EX-99.(A)(1)(YYY)	ROYALTY PHARMA STATEMENT REGARDING WITHDRAWAL OF ELAN LAWSUIT Elan’s US Lawsuit Was Entirely Without Merit, Royalty Pharma Says Voluntary Withdrawal Confirms that Disclosures Have Been Full and Accurate, and Investors Have All Information Needed to C Exhibit (a)(1)(YYY) ROYALTY PHARMA STATEMENT REGARDING WITHDRAWAL OF ELAN LAWSUIT Elan’s US Lawsuit Was Entirely Without Merit, Royalty Pharma Says Voluntary Withdrawal Confirms that Disclosures Have Been Full and Accurate, and Investors Have All Information Needed to Consider Royalty Pharma’s Increased Tender Offer New York – June 10, 2013 - Royalty Pharma announced today that Elan voluntarily withdrew the lawsuit it had filed on an expedited basis only one week ago in New York federal court.
June 11, 2013	EX-99.1	Elan Issues Open Letter Urging Shareholders to Vote Today IN FAVOR of All Four EGM Resolutions EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Issues Open Letter Urging Shareholders to Vote Today IN FAVOR of All Four EGM Resolutions Dublin, Ireland - June 11, 2
June 11, 2013	EX-99.(A)(1)(ZZZ)	EX-99.(A)(1)(ZZZ) EX-99.(A)(1)(ZZZ) 7 dp38904ex-a1zzz.htm EXHIBIT (A)(1)(ZZZ) Exhibit (a)(1)(ZZZ) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION For immediate release 11 June 2013 IN ROYALTY PHARMA’S VIEW, ELAN’S EGM CIRCULAR IS MISLEADING AND OMITS KEY INFORMATI
June 11, 2013	EX-99.(A)(1)(UUU)	ELAN SHAREHOLDERS FACE AN IMPORTANT DECISION ON JUNE 17TH On June 17, 2013, Elan shareholders will be asked to vote on four proposed resolutions at an Extraordinary General Meeting of Elan shareholders. Royalty Pharma has offered to acquire Elan shar EX-99.(A)(1)(UUU) 2 dp38904ex-a1uuu.htm EXHIBIT (A)(1)(UUU) Exhibit (a)(1)(UUU) ELAN SHAREHOLDERS FACE AN IMPORTANT DECISION ON JUNE 17TH On June 17, 2013, Elan shareholders will be asked to vote on four proposed resolutions at an Extraordinary General Meeting of Elan shareholders. Royalty Pharma has offered to acquire Elan shares for $13 per share in cash, plus a contingent value right (CVR) of u
June 11, 2013	EX-99.(A)(1)(BBBB)	/s/ Gregory A. Markel Exhibit (a)(1)(BBBB) UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ELAN CORPORATION, PLC, Plaintiff, -against- RP MANAGEMENT, LLC, ECHO PHARMA ACQUISITION LIMITED, RPI US PARTNERS, LP, RPI US PARTNERS II, LP, RPI INTERNATIONAL PARTNERS, LP and RPI INTERNATIONAL PARTNERS II, LP, Defendants.
June 11, 2013	EX-99.(A)(23)	Elan Issues Open Letter Urging Shareholders to Vote Today IN FAVOR of All Four EGM Resolutions Exhibit (a)(23) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Issues Open Letter Urging Shareholders to Vote Today IN FAVOR of All Four EGM Resolutions Dublin, Ireland - June 11, 2013 - Elan Corporation, plc (NYSE: ELN) (Elan or the Company) today issued a letter urging shareholders to protect the value of their investment in Elan by rejecting Royalty Pharma’s grossly inadequate offer to acquire Elan and by voting FOR all four resolutions in connection with Elan’s fast approaching Extraordinary General Meeting (EGM).
June 11, 2013	EX-99.(A)(1)(CCCC)	11 June 2013 Further Increased Offer Echo Pharma Acquisition Limited (“Royalty Pharma”) Elan Corporation, plc Shareholder Q&A DO NOT DEVIATE FROM THE Q&A OR OFFER ANY PERSONAL COMMENT This Q&A has been reviewed by the client’s legal and financial adv EX-99.(A)(1)(CCCC) 10 dp38904ex-a1cccc.htm EXHIBIT (A)(1)(CCCC) Exhibit (a)(1)(CCCC) 11 June 2013 Further Increased Offer By Echo Pharma Acquisition Limited (“Royalty Pharma”) for Elan Corporation, plc (“Elan”) Shareholder Q&A DO NOT DEVIATE FROM THE Q&A OR OFFER ANY PERSONAL COMMENT This Q&A has been reviewed by the client’s legal and financial advisers, and approved by the Takeover Panel. The Q&
June 11, 2013	CORRESP	- CORRESP 1 filename1.htm Elan Corporation, plc Treasury Building, Lower Grand Canal St. Dublin 2, Ireland T +353 1 709-4000 F +353 1 709-4700 Mr. Jim B. Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance US Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 USA June 11, 2013 Re: Elan Corporation, plc Form 20-F for Fiscal Year ended December 31, 201
June 11, 2013	EX-99.(A)(1)(AAAA)	IN ROYALTY PHARMA’S VIEW, ELAN’S EGM CIRCULAR IS MISLEADING AND OMITS KEY INFORMATION THAT ELAN SHAREHOLDERS NEED TO MAKE AN INFORMED DECISION IF ELAN STOCKHOLDERS APPROVE ANY OF THE FOUR PROPOSED TRANSACTIONS, ROYALTY PHARMA WILL BE REQUIRED TO LAPS Exhibit (a)(1)(AAAA) IN ROYALTY PHARMA’S VIEW, ELAN’S EGM CIRCULAR IS MISLEADING AND OMITS KEY INFORMATION THAT ELAN SHAREHOLDERS NEED TO MAKE AN INFORMED DECISION IF ELAN STOCKHOLDERS APPROVE ANY OF THE FOUR PROPOSED TRANSACTIONS, ROYALTY PHARMA WILL BE REQUIRED TO LAPSE ITS OFFER(i),(ii) ROYALTY PHARMA RECOMMENDS ELAN SHAREHOLDERS VOTE “AGAINST” EACH OF THE ELAN RESOLUTIONS AT THE ELAN EXTRAORDI
June 11, 2013	EX-99.(A)(1)(XXX)	ROYALTY PHARMA STATEMENT REGARDING WITHDRAWAL OF ELAN LAWSUIT Elan’s US Lawsuit Was Entirely Without Merit, Royalty Pharma Says Voluntary Withdrawal Confirms that Disclosures Have Been Full and Accurate, and Investors Have All Information Needed to C EX-99.(A)(1)(XXX) 5 dp38904ex-a1xxx.htm EXHIBIT (A)(1)(XXX) Exhibit (a)(1)(XXX) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE ROYALTY PHARMA STATEMENT REGARDING WITHDRAWAL OF ELAN LAWSUIT Elan’s US Lawsuit Was Entirely Wit
June 11, 2013	SC TO-T/A	- FORM SC TO-T/A SC TO-T/A 1 dp38904sctota-a13.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 12 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL ECHO ACQUISITION LU
June 10, 2013	EX-99.(A)(1)(PPP)	Royalty Pharma's Increased Offer of $13.00 up to $15.50 (including CVR) per Elan Share Vote Against Each of Elan's Four Proposals 10 June 2013 00 Summary of Royalty Pharma Offer [ EX-99.(A)(1)(PPP) 13 dp38873ex-a1ppp.htm EXHIBIT (A)(1)(PPP) Exhibit (a)(1)(PPP) Royalty Pharma's Increased Offer of $13.00 up to $15.50 (including CVR) per Elan Share Vote Against Each of Elan's Four Proposals 10 June 2013 00 Summary of Royalty Pharma Offer [] $13.00 in cash per share PLUS a contingent value right (CVR)(1) worth between zero and up to $2.50 per share [] CVR pays: [] $1.00 for FDA
June 10, 2013	EX-99.(A)(1)(TTT)	ELAN CORPORATION PLC EX-99.(A)(1)(TTT) 17 dp38873ex-a1ttt.htm EXHIBIT (A)(1)(TTT) Exhibit (a)(1)(TTT) THE HIGH COURT 2013 No 52 IA MONDAY THE 3RD DAY OF JUNE 2013 BEFORE MR JUSTICE HOGAN IN THE MATTER OF AN INTENDED ACTION BETWEEN ELAN CORPORATION PLC INTENDED PLAINTIFF AND ECHO PHARMA ACQUISITION LIMITED INTENDED DEFENDANT Upon Motion of Counsel for the intended Plaintiff made ex parte to the Court this day and upon
June 10, 2013	EX-99.(A)(1)(NNN)	Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today ADS Shareholders Have Only Three Days to Vote ISS and Glass Lewis Also Recommend Elan Shareholders Vote AGAINST ALL FOUR Resolutions* Royalty Pharma Will Lapse its EX-99.(A)(1)(NNN) 11 dp38873ex-a1nnn.htm EXHIBIT (A)(1)(NNN) Exhibit (a)(1)(NNN) Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today ADS Shareholders Have Only Three Days to Vote ISS and Glass Lewis Also Recommend Elan Shareholders Vote AGAINST ALL FOUR Resolutions* Royalty Pharma Will Lapse its Offer if the Resolutions Are Approved1,2 NEW YORK – June 10, 2013 -
June 10, 2013	EX-99.(A)(1)(OOO)	Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today ADS Shareholders Have Only Three Days to Vote ISS and Glass Lewis Also Recommend Elan Shareholders Vote AGAINST ALL FOUR Resolutions* Royalty Pharma Will Lapse its EX-99.(A)(1)(OOO) 12 dp38873ex-a1ooo.htm EXHIBIT (A)(1)(OOO) Exhibit (a)(1)(OOO) Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today ADS Shareholders Have Only Three Days to Vote ISS and Glass Lewis Also Recommend Elan Shareholders Vote AGAINST ALL FOUR Resolutions* Royalty Pharma Will Lapse its Offer if the Resolutions Are Approved1,2 NEW YORK – June 10, 2013 -
June 10, 2013	EX-99.(A)(1)(QQQ)	ROYALTY PHARMA POSTS INVESTOR PRESENTATION OUTLINING DETAILS OF FURTHER INCREASED OFFER FOR ELAN Urges Shareholders to Vote Against ALL Proposals at Upcoming EGM Early Voting Deadline for ADS Beneficial Holders is this Wednesday at 11:59 PM ET1 Exhibit (a)(1)(QQQ) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE ROYALTY PHARMA POSTS INVESTOR PRESENTATION OUTLINING DETAILS OF FURTHER INCREASED OFFER FOR ELAN Urges Shareholders to Vote Against ALL Proposals at Upcomin
June 10, 2013	EX-99.(A)(1)(RRR)	ROYALTY PHARMA POSTS INVESTOR PRESENTATION SUMMARIZING FURTHER INCREASED OFFER FOR ELAN Urges Shareholders to Vote AGAINST ALL PROPOSALS at Upcoming Elan EGM Royalty Pharma Offers Compelling Immediate Value with Continued Upside participation Voting EX-99.(A)(1)(RRR) 15 dp38873ex-a1rrr.htm EXHIBIT (A)(1)(RRR) Exhibit (a)(1)(RRR) FOR IMMEDIATE RELEASE ROYALTY PHARMA POSTS INVESTOR PRESENTATION SUMMARIZING FURTHER INCREASED OFFER FOR ELAN Urges Shareholders to Vote AGAINST ALL PROPOSALS at Upcoming Elan EGM Royalty Pharma Offers Compelling Immediate Value with Continued Upside participation Voting Deadline for ADS Beneficial Holders in Street N
June 10, 2013	SC 14D9/A	- AMENDMENT NO. 11 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 11) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05 each (Title of Class of Securities) G29539106 (CUSIP Number of C
June 10, 2013	EX-99.(A)(1)(LLL)	ROYALTY PHARMA POSTS FURTHER REVISED OFFER DOCUMENT IN OFFER FOR ELAN CORPORATION, PLC ("ELAN") EX-99.(A)(1)(LLL) 9 dp38873ex-a1lll.htm EXHIBIT (A)(1)(LLL) Exhibit (a)(1)(LLL) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 10 June 2013 ROYALTY PHARMA POSTS FURTHER REVISED OFFER DOCUMENT IN OFFER FOR ELAN CORPORATION
June 10, 2013	EX-99.(A)(1)(EEE)	10 June 2013 Exhibit (a)(1)(EEE) 10 June 2013 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
June 10, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 10, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER 6-K 1 el20130610-6k2.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, L
June 10, 2013	SC TO-T/A	- SC TO-T/A SC TO-T/A 1 dp38873sctota-a12.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 12 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL ECHO ACQUISITION LUX TWO
June 10, 2013	EX-99.(A)(1)(SSS)	THE HIGH COURT EX-99.(A)(1)(SSS) 16 dp38873ex-a1sss.htm EXHIBIT (A)(1)(SSS) Exhibit (a)(1)(SSS) THE HIGH COURT 2013 No. [5600P] ELAN CORPORATION PLC Plaintiff and ECHO PHARMA ACQUISITION LIMITED Defendant PLENARY SUMMONS To the Defendant, Echo Pharma Acquisition Limited, with a registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland. This Plenary Summons is to require that within eight days after the
June 10, 2013	EX-99.(A)(1)(JJJ)	FURTHER REVISED LETTER TO CLIENTS FURTHER INCREASED OFFER For All Ordinary Shares (Including Ordinary Shares Represented by American Depositary Shares) of ELAN CORPORATION, PLC by ECHO PHARMA ACQUISITION LIMITED EX-99.(A)(1)(JJJ) 7 dp38873ex-a1jjj.htm EXHIBIT (A)(1)(JJJ) Exhibit (a)(1)(JJJ) FURTHER REVISED LETTER TO CLIENTS FURTHER INCREASED OFFER For All Ordinary Shares (Including Ordinary Shares Represented by American Depositary Shares) of ELAN CORPORATION, PLC by ECHO PHARMA ACQUISITION LIMITED THE FURTHER INCREASED OFFER AND RELATED WITHDRAWAL RIGHTS WILL EXPIRE AT 8:00 A.M. (NEW YORK CITY TIME) / 1:
June 10, 2013	EX-99.1	Elan Withdraws Lawsuit – Royalty Pharma Made Significant Additional Disclosure EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Withdraws Lawsuit – Royalty Pharma Made Significant Additional Disclosure Dublin, Ireland – June 10, 2013 – Elan Corpo
June 10, 2013	EX-99.(A)(1)(HHH)	FURTHER REVISED ADS LETTER OF TRANSMITTAL To Tender Ordinary Shares represented by American Depositary Shares (ADSs) of ELAN CORPORATION, PLC pursuant to the Further Increased Offer dated June 10, 2013 by ECHO PHARMA ACQUISITION LIMITED Exhibit (a)(1)(HHH) THIS DOCUMENT AND THE FURTHER REVISED OFFER DOCUMENT ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION.
June 10, 2013	EX-99.(A)(1)(FFF)	FURTHER REVISED FORM OF ACCEPTANCE AND AUTHORITY Further Increased Offer ECHO PHARMA ACQUISITION LIMITED ELAN CORPORATION, PLC (the Further Increased Offer) EX-99.(A)(1)(FFF) 3 dp38873ex-a1fff.htm EXHIBIT (A)(1)(FFF) Exhibit (a)(1)(FFF) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take, you are recommended to seek financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other appropriate independent financial adviser who, if you are resident in I
June 10, 2013	EX-99.(A)(1)(KKK)	This announcement is neither an offer to purchase nor a solicitation of an offer to sell ordinary shares, of €0.05 each (“Elan Shares”), of Elan Corporation, plc, a public limited company incorporated under the laws of Ireland (“Elan”), including Ela EX-99.(A)(1)(KKK) 8 dp38873ex-a1kkk.htm EXHIBIT (A)(1)(KKK) Exhibit (a)(1)(KKK) This announcement is neither an offer to purchase nor a solicitation of an offer to sell ordinary shares, of €0.05 each (“Elan Shares”), of Elan Corporation, plc, a public limited company incorporated under the laws of Ireland (“Elan”), including Elan Shares represented by American depositary shares (“Elan ADSs”), and
June 10, 2013	EX-99.(A)(1)(MMM)	ROYALTY PHARMA POSTS FURTHER REVISED OFFER DOCUMENT IN OFFER FOR ELAN CORPORATION, PLC (“ELAN”) EX-99.(A)(1)(MMM) 10 dp38873ex-a1mmm.htm EXHIBIT (A)(1)(MMM) Exhibit (a)(1)(MMM) FOR IMMEDIATE RELEASE ROYALTY PHARMA POSTS FURTHER REVISED OFFER DOCUMENT IN OFFER FOR ELAN CORPORATION, PLC (“ELAN”) NEW YORK- June 10, 2013- Following its announcement on 7 June 2013, Echo Pharma Acquisition Limited ("Royalty Pharma") has today issued a further revised offer document dated 10 June 2013 (the “Further
June 10, 2013	EX-99.(A)(1)(III)	FURTHER REVISED LETTER TO BROKERS, DEALERS, ETC. FURTHER INCREASED OFFER For All Ordinary Shares (Including Ordinary Shares Represented by American Depositary Shares) of ELAN CORPORATION, PLC by ECHO PHARMA ACQUISITION LIMITED EX-99.(A)(1)(III) 6 dp38873ex-a1iii.htm EXHIBIT (A)(1)(III) Exhibit (a)(1)(III) FURTHER REVISED LETTER TO BROKERS, DEALERS, ETC. FURTHER INCREASED OFFER For All Ordinary Shares (Including Ordinary Shares Represented by American Depositary Shares) of ELAN CORPORATION, PLC by ECHO PHARMA ACQUISITION LIMITED THE FURTHER INCREASED OFFER AND RELATED WITHDRAWAL RIGHTS WILL EXPIRE AT 8:00 A.M. (NEW YORK
June 10, 2013	EX-99.1	Elan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender Offer EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender Offer · Royalty Pharma
June 10, 2013	EX-99.(A)(22)	Elan Withdraws Lawsuit – Royalty Pharma Made Significant Additional Disclosure Exhibit (a)(22) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Withdraws Lawsuit – Royalty Pharma Made Significant Additional Disclosure Dublin, Ireland – June 10, 2013 – Elan Corporation, plc (NYSE: ELN) (Elan) today announced a successful result in the litigation Elan commenced one week ago in the United States District Court for the Southern District of New York (the “Court”) to compel corrective disclosure in Royalty Pharma’s tender offer documents.
June 10, 2013	EX-99.(A)(21)	Elan Board Of Directors Unanimously And Without Reservation Rejects Royalty Pharma's Revised Tender Offer EX-99.(A)(21) 2 t1300128ex-a21.htm EXHIBIT (A)(21) Exhibit (a)(21) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Board Of Directors Unanimously And Without Reservation Rejects R
June 10, 2013	EX-99.(A)(1)(GGG)	FURTHER REVISED FORM OF ACCEPTANCE AND AUTHORITY Further Increased Offer ECHO PHARMA ACQUISITION LIMITED ELAN CORPORATION, PLC (the Further Increased Offer) Acceptance of the Further Increased Offer should be received by no later than 1:00 p.m. on 24 EX-99.(A)(1)(GGG) 4 dp38873ex-a1ggg.htm EXHIBIT (A)(1)(GGG) Exhibit (a)(1)(GGG) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take, you are recommended to seek financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other appropriate independent financial adviser who, if you are resident in I
June 7, 2013	SC TO-T/A	- FORM SC TO-T/A SC TO-T/A 1 dp38852sctota-a11.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 11 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL ECHO ACQUISITION LU
June 7, 2013	EX-99.(A)(20)	Elan’s Response to Royalty Pharma Announcement Exhibit (a)(20) FOR IMMEDIATE RELEASE Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan’s Response to Royalty Pharma Announcement Dublin, Ireland – June 7 , 2013 - The Board of Elan Corporation, plc (NYSE : ELN) (Elan) notes today’s announcement regarding the revised offer by Echo Pharma Acquisition Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.
June 7, 2013	EX-99.(A)(1)(WW)	ROYALTY PHARMA ANNOUNCES FURTHER INCREASED OFFER FOR ELAN OF US$13.00 IN CASH PLUS A CONTINGENT VALUE RIGHT OF UP TO US$2.50 PER SHARE1 EX-99.(A)(1)(WW) 4 dp38852ex-a1ww.htm EXHIBIT (A)(1)(WW) Exhibit (a)(1)(WW) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION For immediate release – 7 June 2013 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM AN
June 7, 2013	EX-99.(A)(1)(ZZ)	EX-99.(A)(1)(ZZ) EX-99.(A)(1)(ZZ) 7 dp38743ex-a1zz.htm EXHIBIT (A)(1)(ZZ) Exhibit (a)(1)(ZZ)
June 7, 2013	EX-99.1	Elan’s Response to Royalty Pharma Announcement EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan’s Response to Royalty Pharma Announcement Dublin, Ireland – June 7 , 2013 - The Board of Elan Corporation, plc (NYSE :
June 7, 2013	EX-99.(B)(7)	SENIOR SECURED BRIDGE CREDIT AGREEMENT dated as of [________ __], 2013 ROYALTY PHARMA INVESTMENTS, as the Borrower, CERTAIN AFFILIATES OF ROYALTY PHARMA INVESTMENTS FROM TIME TO TIME PARTY HERETO, THE LENDERS FROM TIME TO TIME PARTY HERETO, BANK OF A EX-99.(B)(7) 12 dp38743ex-b7.htm EXHIBIT (B)(7) Exhibit (b)(7) Published CUSIP Number [] SENIOR SECURED BRIDGE CREDIT AGREEMENT dated as of [ ], 2013 among ROYALTY PHARMA INVESTMENTS, as the Borrower, CERTAIN AFFILIATES OF ROYALTY PHARMA INVESTMENTS FROM TIME TO TIME PARTY HERETO, THE LENDERS FROM TIME TO TIME PARTY HERETO, BANK OF AMERICA, N.A., as Administrative Agent, and JPMORGAN CHASE BANK, N
June 7, 2013	EX-99.(A)(1)(VV)	Royalty Pharma Acceptances Announcement EX-99.(A)(1)(VV) 3 dp38852ex-a1vv.htm EXHIBIT (A)(1)(VV) Exhibit (a)(1)(VV) Royalty Pharma Acceptances Announcement NEW YORK – June 07, 2013 – In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited (“Royalty Pharma”) today announced acceptance levels of its Increased Offer for Elan Corporation (NYSE: ELN). Backgr
June 7, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER 6-K 1 el20130607-6k.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lo
June 7, 2013	EX-99.(A)(1)(YY)	Echo Pharma Acquisition Ltd EX-99.(A)(1)(YY) 6 dp38743ex-a1yy.htm EXHIBIT (A)(1)(YY) Exhibit (a)(1)(YY) Echo Pharma Acquisition Ltd To the Shareholders and ADS Holders of Elan Corporation, plc: On 2 May 2013, Echo Pharma Acquisition Limited (“we” or “our”) commenced a tender offer to purchase all of the outstanding ordinary shares of Elan Corporation, plc (“Elan”), including those ordinary shares represented by American depo
June 7, 2013	EX-99.(A)(1)(DDD)	v. EX-99.(A)(1)(DDD) 11 dp38852ex-a1ddd.htm EXHIBIT (A)(1)(DDD) Exhibit (a)(1)(DDD) UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ELAN CORPORATION, PLC Plaintiff, Case No. 13-cv-3758 v. ORDER TO SHOW CAUSE FOR PRELIMINARY INJUNCTION, TEMPORARY RESTRAINING ORDER, AND EXPEDITED DISCOVERY RP MANAGEMENT, LLC, ECHO PHARMA CQUISITION LIMITED, RPI US PARTNERS, LP, RPI US PARTNERS II, LP, RPI IN
June 7, 2013	EX-99.(B)(8)	AMENDED AND RESTATED CREDIT AGREEMENT dated as of [________ __], 2013 RPI FINANCE TRUST, as the Borrower, CERTAIN AFFILIATES OF RPI FINANCE TRUST FROM TIME TO TIME PARTY HERETO, THE LENDERS FROM TIME TO TIME PARTY HERETO, BANK OF AMERICA, N.A., as Ad EX-99.(B)(8) 13 dp38743ex-b8.htm EXHIBIT (B)(8) Exhibit (b)(8) Published CUSIP Number [74966UAF7difr] (5¼ Year Term Facility) Published CUSIP Number [74966UAE0difr] (6¾ Year Term Facility) Published CUSIP Number [74966UAD2difr] (New Term Facility) Published CUSIP Number [] (Acquisition Term Facility) AMENDED AND RESTATED CREDIT AGREEMENT dated as of [ ], 2013 among RPI FINANCE TRUST, as the Borrow
June 7, 2013	EX-99.(A)(1)(UU)	Royalty Pharma Acceptances Announcement EX-99.(A)(1)(UU) 2 dp38852ex-a1uu.htm EXHIBIT (A)(1)(UU) Exhibit (a)(1)(UU) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE Royalty Pharma Acceptances Announcement NEW YORK – June 07, 2013 – In accordance with Rule 17.1 and
June 7, 2013	EX-99.(A)(1)(BBB)	CONTINGENT VALUE RIGHTS AGREEMENT EX-99.(A)(1)(BBB) 9 dp38743ex-a1bbb.htm EXHIBIT (A)(1)(BBB) Exhibit (a)(1)(BBB) Execution Version CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of June 7, 2013 (this “Agreement”), is entered into by and among ECHO PHARMA ACQUISITION LIMITED, a private company incorporated under the laws of Ireland (the “Buyer”), and The Colbent Corporation, as Rights Agent (the
June 7, 2013	SC 14D9/A	- AMENDMENT NO. 10 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D−9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05 each (Title of Class of Securities) G29539106 (CUSIP Number of C
June 7, 2013	EX-99.(A)(1)(AAA)	Extraordinary General Meeting of Elan Corporation, plc (the “Company”) – 17 June 2013 The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 a.m. (New York City time) on 13 June 2013, for action to be t Exhibit (a)(1)(AAA) Extraordinary General Meeting of Elan Corporation, plc (the “Company”) – 17 June 2013 The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 a.
June 7, 2013	EX-99.(A)(1)(CCC)	NATURE OF THE ACTION EX-99.(A)(1)(CCC) 10 dp38743ex-a1ccc.htm EXHIBIT (A)(1)(CCC) Exhibit (a)(1)(CCC) UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ELAN CORPORATION, PLC, Plaintiff, Case No. 13-cv- v. RP MANAGEMENT, LLC, ECHO PHARMA ACQUISITION LIMITED, RPI US PARTNERS, LP, RPI US PARTNERS II, LP, RPI INTERNATIONAL PARTNERS, LP and RPI INTERNATIONAL PARTNERS II, LP, Defendants. COMPLAINT Plaintiff Elan Co
June 7, 2013	EX-99.(A)(1)(XX)	Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share EX-99.(A)(1)(XX) 5 dp38743ex-a1xx.htm EXHIBIT (A)(1)(XX) Exhibit (a)(1)(XX) Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share CVR Allows Shareholders to Participate in Tysabri Royalty Upside for all Indications and Cash Flows, Pre- and Post-Patent Expiration Offer Represents Premium of 56% to 97% to Elan’s Undisturbed
June 6, 2013	SC TO-T/A	- FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No.
June 6, 2013	EX-99.(A)(1)(TT)	Royalty Pharma Announces Extension of its Increased Offer EX-99.(A)(1)(TT) 3 dp38831ex-a1tt.htm EXHIBIT (A)(1)(TT) Exhibit (a)(1)(TT) FOR IMMEDIATE RELEASE Royalty Pharma Announces Extension of its Increased Offer NEW YORK - June 6, 2013 - Royalty Pharma today announces that the closing date for its Increased Offer made for Elan Corporation, plc (NYSE: ELN) on 23 May 2013 is being extended until 1:00 p.m. (Irish time) / 8:00 a.m. (New York City time) on
June 6, 2013	SC 14D9/A	- AMENDMENT NO. 9 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D−9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05 each (Title of Class of Securities) G29539106 (CUSIP Number of Cl
June 6, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 6, 2013	EX-99.(A)(17)	Elan Injunction: ROYALTY PHARMA ISSUES GROSSLY MISLEADING STATEMENT ELAN TO PURSUE ROYALTY PHARMA'S MISREPRESENTATIONS AND LACK OF DISCLOSURE WITH RELEVANT AUTHORITIES US DISTRICT COURT ISSUES TEMPORARY RESTRAINING ORDER EX-99.(A)(17) 2 t1300123-ex99a17.htm EXHIBIT (A)(17) Exhibit (a)(17) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: 800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Injunction: ROYALTY PHARMA ISSUES GROSSLY MISLEADING STATEMENT ELA
June 6, 2013	EX-99.(A)(18)	Elan’s response to irish takeover panel rulings EX-99.(A)(18) 2 t1300125-exa18.htm EXHIBIT (A)(18) Exhibit (a)(18) For Immediate Release Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: + 44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: + 1-212-687-8080 Elan’s response to irish takeover panel rulings · Royalty pharma MU
June 6, 2013	EX-99.(A)(1)(SS)	Royalty Pharma Announces Extension of its Increased Offer EX-99.(A)(1)(SS) 2 dp38831ex-a1ss.htm EXHIBIT (A)(1)(SS) Exhibit (a)(1)(SS) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 6 June 2013 Royalty Pharma Announces Extension of its Increased Offer Royalty Pharma today announces
June 6, 2013	EX-99.(A)(19)	CORPORATE PARTICIPANTS EX-99.(A)(19) 3 t1300125-exa19.htm EXHIBIT (A)(19) Exhibit (a)(19) JUNE 05, 2013 / 01:30PM GMT, DRX.I - Elan Corporation, PLC at Jefferies Global Healthcare Conference CORPORATE PARTICIPANTS Kelly Martin Elan Corporation - CEO CONFERENCE CALL PARTICIPANTS Corey Davis Jefferies & Company - Analyst PRESENTATION Corey Davis - Jefferies & Company - Analyst Thanks for coming. I'm Corey Davis. I cover s
June 6, 2013	EX-99.1	ELAN’S RESPONSE TO IRISH TAKEOVER PANEL RULINGS ● ROYALTY PHARMA MUST LAPSE OFFER IF ANY OF THE EGM RESOLUTIONS ARE PASSED ● ROYALTY PHARMA PROXY STATEMENT BREACHED TAKEOVER RULES EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: + 44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: + 1-212-687-8080 ELAN’S RESPONSE TO IRISH TAKEOVER PANEL RULINGS ● ROYALTY PHARMA MUST LAPSE OFFER IF ANY OF THE EGM RESOLUTIONS ARE PASSE
June 6, 2013	SC 14D9/A	- AMENDMENT NO. 8 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05 each (Title of Class of Securities) G29539106 (CUSIP Number of Cl
June 5, 2013	6-K	Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2013 Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of princ
June 5, 2013	EX-99.(A)(14)	ELAN AWARDED INJUNCTION AGAINST ROYALTY PHARMA IN IRELAND Elan fILES Temporary Restraining Order AGAINST ROYALTY PHARMA IN US EX-99.(A)(14) 2 t1300118exa14.htm EXHIBIT (A)(14) Exhibit (a)(14) For Immediate Release Investor Relations: Chris Burns Ph: 800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN AWARDED INJUNCTION AGAINST ROYALTY PHARMA IN IRELAND Elan fILES Tempo
June 5, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER 6-K 1 el20130605-6k.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lo
June 5, 2013	EX-99.(A)(16)	Time Sensitive Materials Depositary's Notice of Extraordinary General Meeting of ELAN CORPORATION, PLC (the “Company”) June 17, 2013 To be counted, your Voting Instructions need to be received by the Depositary prior to 3:00 P.M. (New York City time) EX-99.(A)(16) 4 t1300118exa16.htm EXHIBIT (A)(16) Exhibit (a)(16) Time Sensitive Materials Depositary's Notice of Extraordinary General Meeting of ELAN CORPORATION, PLC (the “Company”) June 17, 2013 To be counted, your Voting Instructions need to be received by the Depositary prior to 3:00 P.M. (New York City time) on June 13, 2013. ADSs: American Depositary Shares (“ADSs”), some of which are evid
June 5, 2013	EX-99.1	ELAN INJUNCTION; ROYALTY PHARMA ISSUES GROSSLY MISLEADING STATEMENT ELAN TO PURSUE ROYALTY PHARMA'S MISREPRESENTATIONS AND LACK OF DISCLOSURE WITH RELEVANT AUTHORITIES US DISTRICT COURT ISSUES TEMPORARY RESTRAINING ORDER EX-99.1 2 el20130605-ex991.htm PRESS RELEASE EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: 800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN INJUNCTION; ROYALTY PHARMA ISSUES GROSSLY MISLEADING STATEMENT ELAN TO PURSUE
June 5, 2013	SC 14D9/A	- AMENDMENT NO. 7 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05 each (Title of Class of Securities) G29539106 (CUSIP Number of Cl
June 5, 2013	EX-99.(A)(15)	ELAN ANNOUNCES OUTCOME OF IRISH HIGH COURT INJUNCTION EX-99.(A)(15) 3 t1300118exa15.htm EXHIBIT (A)(15) Exhibit (a)(15) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: 800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN ANNOUNCES OUTCOME OF IRISH HIGH COURT INJUNCTION · ROYALTY PHARMA TO
June 5, 2013	SC TO-T/A	- FORM SC TO-T/A AMENDMENT NO. 9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No.
June 5, 2013	EX-99.A1RR	ROYALTY PHARMA STATEMENT REGARDING ELAN LAW SUITS Royalty Pharma Deplores What it Believes are Efforts by Elan to Deprive Shareholders of an Opportunity to Consider Royalty Pharma Offer Elan Withdraws Law Suit in Ireland After Court Confirms Jurisdic Exhibit (a)(1)(RR) ROYALTY PHARMA STATEMENT REGARDING ELAN LAW SUITS Royalty Pharma Deplores What it Believes are Efforts by Elan to Deprive Shareholders of an Opportunity to Consider Royalty Pharma Offer Elan Withdraws Law Suit in Ireland After Court Confirms Jurisdiction of Irish Takeover Panel Elan Law Suit in the United States is Entirely Without Merit, Royalty Pharma Says New York - June 5, 2013 - Royalty Pharma announced today that on Tuesday, June 4, 2013, Elan withdrew a lawsuit it had filed on an emergency basis only the previous day.
June 4, 2013	6-K	Current Report of Foreign Issuer - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 4, 2013	EX-99.1	Investor Relations: Chris Burns Ph: 800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: 800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN ANNOUNCES OUTCOME OF IRISH HIGH COURT INJUNCTION ● ROYALTY PHARMA TO REFRAIN FROM PUBLISHING ITS PROXY STATEMENT TO SHAREH
June 4, 2013	EX-99.1	Investor Relations: Media Relations: Chris Burns Emer Reynolds Ph: 800-252-3526 Ph: + 353-1-709-4022 David Marshall Jonathan Birt/FTI Counseling Ph: + 353-1-709-4444 Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations: Chris Burns Emer Reynolds Ph: 800-252-3526 Ph: + 353-1-709-4022 David Marshall Jonathan Birt/FTI Counseling Ph: + 353-1-709-4444 Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN AWARDED INJUNCTION AGAINST ROYALTY PHARMA IN IRELAND ELAN FILES TEMPORARY RESTRAINING ORDER AGAINST ROYALTY PHARMA IN US
June 4, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 4, 2013	SC TO-T/A	- FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 8 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL ECHO ACQUISITION LUX TWO SARL ECHO ACQUISITION
June 4, 2013	EX-99.(A)(1)(QQ)	ISS Recommends Shareholders Vote AGAINST All Elan Proposed Transactions Royalty Pharma Urges Shareholders to Follow the Recommendations of ISS and Vote AGAINST Elan’s Proposed Acquisition of Theravance and AOP, the Divestment of ELN005, As Well As it Exhibit (a)(1)(QQ) ISS Recommends Shareholders Vote AGAINST All Elan Proposed Transactions Royalty Pharma Urges Shareholders to Follow the Recommendations of ISS and Vote AGAINST Elan’s Proposed Acquisition of Theravance and AOP, the Divestment of ELN005, As Well As its $200 Million Share Buyback Leading Independent Shareholder Advisory Firm Says Royalty Pharma Offer “Appears to Offer More Value f
June 3, 2013	EX-99.1	Elan Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised Offer Royalty Pharma's Revised Offer Grossly Undervalues Elan's Tysabri and Cash Value alone Royalty Pharma's Revised Offer - Misleading and Simplistic1 Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: 800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised Offer Royalty Pharma's Revised Offer Gro
June 3, 2013	EX-99.(A)(13)	Elan Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised Offer Royalty Pharma's Revised Offer Grossly Undervalues Elan's Tysabri and Cash Value alone Royalty Pharma's Revised Offer - Misleading and Simplistic1 EX-99.(A)(13) 3 t1300115exa13.htm EXHIBIT (A)(13) Exhibit (a)(13) FOR IMMEDIATE RELEASE Investor Relations: Chris Burns Ph: 800-252-3526 David Marshall Ph:+ 353-1-709-4444 Media Relations: Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Issues Response Document Further Detailing Inadequacy of Royalty Phar
June 3, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of pri
June 3, 2013	SC 14D9/A	- AMENDMENT NO. 6 TO SCHEDULE 14D-9 SC 14D9/A 1 t1300115sc14d9a.htm AMENDMENT NO. 6 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05
June 3, 2013	EX-99.(A)(12)	FURTHER REASONS TO REJECT THE WHOLLY INADEQUATE REVISED ROYALTY PHARMA OFFER EX-99.(A)(12) 2 t1300015exa12.htm EXHIBIT (A)(12) Exhibit (a)(12) FURTHER REASONS TO REJECT THE WHOLLY INADEQUATE REVISED ROYALTY PHARMA OFFER THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the action you should take, you are recommended to seek financial advice immediately from your stockbroker, bank manager, solicitor, accountant, fund manager or
May 31, 2013	EX-99.(A)(1)(LL)	Form of Proxy GREEN Proxy Card Your proxy is being solicited by Echo Pharma Acquisition Limited ("Royalty Exhibit (a)(1)(LL) Form of Proxy GREEN Proxy Card Your proxy is being solicited by Echo Pharma Acquisition Limited ("Royalty Pharma") for use at the Extraordinary General Meeting of Elan Corporation, plc to be held at the O'Callaghan Davenport Hotel, 8/10 Merrion Street Lower, Dublin 2, Ireland at 10:00 a.
May 31, 2013	EX-99.(A)(1)(NN)	NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION EX-99.(A)(1)(NN) 5 dp38614ex-a1nn.htm EXHIBIT (A)(1)(NN) Exhibit (a)(1)(NN) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION For immediate release 31 May 2013 ROYALTY PHARMA RESPONDS TO ELAN’S TYSABRI VALUATION Royalty Pharma is today issuing a pr
May 31, 2013	EX-99.(A)(1)(PP)	Royalty Pharma's Response to Elan's Tysabri Valuation [GRAPHIC OMITTED] 31 May 2013 Response to Elan's Valuation of 29 May 2013 Exhibit (a)(1)(PP) Royalty Pharma's Response to Elan's Tysabri Valuation [GRAPHIC OMITTED] 31 May 2013 Response to Elan's Valuation of 29 May 2013 cov Elan's Valuation of Tysabri is Far Too High* - [] Elan's Tysabri valuation "analysis" provides limited detail and relies only selectively on consensus numbers* [] Elan's valuation assumptions are above full street consensus estimates and do not reflect a balanced risk assessment even if one believes in Tysabri (as we do)* [] Elan asks shareholders to imagine a very hypothetical world where Elan is not laden with substantial expenses and is not funding expensive late-stage development programs (i.
May 31, 2013	EX-99.(A)(11)	ISS Presentation May 30, 2013 Exhibit (a)(11) ISS Presentation May 30, 2013 Agenda 1. Introduction 2. Tysabri As An Asset 3. Incremental Strategic Transactions A. Theravance Royalty Portfolio B. AOP & Newbridge C. Speranza Therapeutics 4. Capital Structure Discipline 5. Royalty Pharma Specifics - 2 - 1. Introduction Introduction Our objectives….. ► P&L Growth: Self Funding To Support Long Cycle Business ► Establish Optionality
May 31, 2013	EX-99.(A)(1)(KK)	Echo Pharma Acquisition Ltd EX-99.(A)(1)(KK) 2 dp38614ex-a1kk.htm EXHIBIT (A)(1)(KK) Exhibit (a)(1)(KK) Echo Pharma Acquisition Ltd To the Shareholders and ADS Holders of Elan Corporation, plc: On 2 May 2013, Echo Pharma Acquisition Limited (“we” or “our”) commenced a tender offer to purchase all of the outstanding ordinary shares of Elan Corporation, plc (“Elan”), including those ordinary shares represented by American depo
May 31, 2013	EX-99.(A)(1)(MM)	Extraordinary General Meeting of Elan Corporation, plc (the “Company”) – 17 June 2013 The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 a.m. (New York City time) on 13 June 2013, for action to be t EX-99.(A)(1)(MM) 4 dp38614ex-a1mm.htm EXHIBIT (A)(1)(MM) Exhibit (a)(1)(MM) Extraordinary General Meeting of Elan Corporation, plc (the “Company”) – 17 June 2013 The Voting Instructions must be signed, completed and received at the indicated address prior to 10:00 a.m. (New York City time) on 13 June 2013, for action to be taken To submit a voting instruction by mail, mark, sign date and return th
May 31, 2013	SC 14D9/A	- AMENDMENT NO. 5 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05 each (Title of Class of Securities) G29539106 (CUSIP Number of Cl
May 31, 2013	EX-99.(A)(1)(OO)	ROYALTY PHARMA RESPONDS TO ELAN’S TYSABRI VALUATION EX-99.(A)(1)(OO) 6 dp38614ex-a1oo.htm EXHIBIT (A)(1)(OO) Exhibit (a)(1)(OO) For immediate release ROYALTY PHARMA RESPONDS TO ELAN’S TYSABRI VALUATION NEW YORK – 31 May 2013 – Royalty Pharma is today issuing a presentation outlining why it believes Elan’s (NYSE: ELN) valuation of Tysabri, as set out in materials released by Elan on 29 May 2013, is far too high. The presentation may be found at http
May 31, 2013	SC TO-T/A	- FORM SC TO-T/A SC TO-T/A 1 dp38614sctota-a7.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 7 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SAR
May 30, 2013	EX-99.(A)(1)(II)	ROYALTY PHARMA RESPONSE TO ELAN’S “CATEGORICAL VIEW ON VALUE” EX-99.(A)(1)(II) 3 dp38581a1ii.htm EXHIBIT (A)(1)(II) Exhibit (a)(1)(II) ROYALTY PHARMA RESPONSE TO ELAN’S “CATEGORICAL VIEW ON VALUE” NEW YORK – 30 May 2013 – Commenting on Elan’s (NYSE: ELN) announcement of last night, Pablo Legorreta, Chief Executive Officer of Royalty Pharma, said: “In its announcement, Elan’s Board makes the unrealistic claim that the Tysabri royalty it owns is worth between
May 30, 2013	EX-99.(A)(10)	Elan Provides Shareholders with Categorical View on Value EX-99.(A)(10) 87 t1300109ex-a10.htm EXHIBIT (A)(10) Exhibit (a)(10) FOR IMMEDIATE RELEASE Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 Elan Provides Shareholders with Categorical View on Value § The under
May 30, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of prin
May 30, 2013	SC 14D9/A	- AMENDMENT NO. 4 TO SCHEDULE 14D-9 SC 14D9/A 1 t1300109-14d9a.htm AMENDMENT NO. 4 TO SCHEDULE 14D-9 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) ELAN CORPORATION, PLC (Name of Subject Company) ELAN CORPORATION, PLC (Names of Person Filing Statement) Ordinary Shares, par value €0.05
May 30, 2013	EX-99.(A)(1)(HH)	NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION EX-99.(A)(1)(HH) 2 dp38581a1hh.htm EXHIBIT (A)(1)(HH) (a)(1)(HH) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION For immediate release 30 May 2013 RESPONSE TO ELAN’S “CATEGORICAL VIEW ON VALUE” Commenting on Elan’s announcement of last night, Pab
May 30, 2013	EX-99.1	ELAN TO PRESENT AT THE JEFFERIES 2013 GLOBAL HEALTHCARE CONFERENCE Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN TO PRESENT AT THE JEFFERIES 2013 GLOBAL HEALTHCARE CONFERENCE DUBLIN, Ireland – May 30, 2013 - Elan Corporation, plc (NY
May 30, 2013	SC TO-T/A	- EXHIBIT SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 6 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL ECHO ACQUISITION LUX TWO SARL ECHO ACQUISITION
May 30, 2013	EX-99.(A)(6)	SHARE PURCHASE AGREEMENT by and between Dr. Rudolf Stefan Widmann born 24.03.1957 Wintergasse 85/1b 3002 Purkersdorf (the "Seller") ON THE ONE HAND SASR Neunundvierzigste Beteiligungsverwaltung GmbH FN 395723 x Tuchlauben 17 1010 Vienna (the "Purchas EX-99.(A)(6) 2 t1300109ex99a6.htm EXHIBIT (A)(6) Exhibit (a)(6) SHARE PURCHASE AGREEMENT by and between Dr. Rudolf Stefan Widmann born 24.03.1957 Wintergasse 85/1b 3002 Purkersdorf (the "Seller") ON THE ONE HAND and SASR Neunundvierzigste Beteiligungsverwaltung GmbH FN 395723 x Tuchlauben 17 1010 Vienna (the "Purchaser 1") and Elan Corporation, plc Registered number 30356 Treasury Building Lower G
May 30, 2013	EX-99.(A)(1)(JJ)	NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION EX-99.(A)(1)(JJ) 4 dp38581a1jj.htm EXHIBIT (A)(1)(JJ) (a)(1)(JJ) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION For immediate release 30 May 2013 STATEMENT REGARDING ROYALTY PHARMA OFFER FOR ELAN In its announcement dated 30 May 2013 recommendin
May 30, 2013	6-K	Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May, 2013. Commission File Number 001-13896 Elan Corporation, plc (Translation of registrant’s name into English) Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland (Address of prin
May 30, 2013	EX-99.1	ELAN PROVIDES SHAREHOLDERS WITH CATEGORICAL VIEW ON VALUE Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Relations: Media Relations Chris Burns Ph: + 1-800-252-3526 David Marshall Ph:+ 353-1-709-4444 Emer Reynolds Ph: + 353-1-709-4022 Jonathan Birt/FTI Consulting Ph: +44-751-559-7858 Jamie Tully/Sard Verbinnen & Co Ph: +1-212-687-8080 ELAN PROVIDES SHAREHOLDERS WITH CATEGORICAL VIEW ON VALUE § The underlying value of Tysabri is $11.85 per share1. The upside
May 29, 2013	EX-99.A1GG	ROYALTY PHARMA RECOMMENDS ELAN SHAREHOLDERS VOTE “NO” ON EACH OF THE ELAN RESOLUTIONS AT THE ELAN EXTRAORDINARY GENERAL MEETING Elan’s proposed transactions offer no coherent strategy and are not in the best interests of Elan or its shareholders Roya Exhibit (a)(1)(GG) ROYALTY PHARMA RECOMMENDS ELAN SHAREHOLDERS VOTE “NO” ON EACH OF THE ELAN RESOLUTIONS AT THE ELAN EXTRAORDINARY GENERAL MEETING Elan’s proposed transactions offer no coherent strategy and are not in the best interests of Elan or its shareholders Royalty Pharma’s offer will lapse if either the Theravance Transaction or the AOP acquisition is approved New York - 29 May 2013 - Royalty Pharma announces its recommendation that the shareholders of Elan Corporation, plc (NYSE: ELN) vote “NO” on each of the four proposals offered by Elan at its upcoming extraordinary general meeting on June 17, 2013.
May 29, 2013	SC TO-T/A	- FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Amendment No. 5 ELAN CORPORATION, PLC (Name of Subject Company (Issuer)) ECHO PHARMA ACQUISITION LIMITED (Names of Filing Persons (Offeror)) ECHO ACQUISITION LUX THREE SARL ECHO ACQUISITION LUX TWO SARL ECHO ACQUISITION
May 29, 2013	EX-99.2	ELAN CORPORATION, PLC AND SUBSIDIARIES EX-99.2 3 d544284dex992.htm EX-99.2 Exhibit 99.2 ELAN CORPORATION, PLC AND SUBSIDIARIES CAPITALIZATION Tysabri Transaction On February 6, 2013, Elan Corporation, plc (“Elan”) announced that it had agreed to transfer to Biogen Idec International Holding Ltd., an affiliate of Biogen Idec Inc. (“Biogen Idec”), all of Elan’s interest in the intellectual property and other assets related to the develop

ELN / Elan Corp. Plc - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)